Glycominds entered into a research agreement with Fox Chase Cancer Center (FCCC) to develop a new blood test for breast cancer.
“Glycominds’ antiglycan antibodies biomarkers approach together with FCCC’s excellent patient records, samples, and clinical know-how give this project a high basis for success,” asserts Nir Dotan, Ph.D., Glycominds’ cofounder, CTO, and vp of R&D.
“I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer,” notes Andrew K. Godwin, Ph.D., director of the clinical molecular genetics laboratory and the biosample repository at FCCC.